SPRB News and Press, Spruce Biosciences Inc. From 10/06/25

2025-10-06 09:18:59 ET DENVER, Colo., Oct 06, 2025 ( 247marketnews.com )- Wall Street kicks off the week with a burst of biotech momentum, massive AI infrastructure bets, and the continued rise of a new entertainment real estate disruptor. Spruce Biosciences (NASDAQ:SPRB) is in ...

Breakthrough Therapy Designation Supported by Integrated Long-Term Clinical Data Demonstrating Normalization in Cerebral Spinal Fluid Heparan Sulfate Non-Reducing End (CSF HS-NRE) U.S. FDA Confirmed that CSF HS-NRE is a Surrogate Biomarker Reasonably Likely to Predict Clinical Benefit and...

2025-09-15 07:42:20 ET More on Spruce Biosciences Seeking Alpha’s Quant Rating on Spruce Biosciences Historical earnings data for Spruce Biosciences Financial information for Spruce Biosciences Read the full article on Seeking Alpha For further...

Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, announced that it will resume trading on the Nasdaq Capital Market at the market open today, Se...

Integrated Long-Term Clinical Data of Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) Demonstrates Profound and Durable Efficacy and Safety in Patients with Sanfilippo Syndrome Type B (MPS IIIB) Biologics License Application Submission of TA-ERT for MPS IIIB Anticipated in First Qu...

TA-ERT Profoundly and Durably Lowered Cerebral Spinal Fluid Heparan Sulfate Non-Reducing End (CSF HS-NRE), the Factor Responsible for Neurodegeneration in MPS IIIB U.S. FDA Confirmed that CSF HS-NRE is a Surrogate Biomarker Reasonably Likely to Predict Clinical Benefit and Could Serve as ...

Xenon Pharmaceuticals Inc. (XENE) is expected to report $-1.03 for Q2 2025 Gaia Inc. (GAIA) is expected to report $-0.08 for Q2 2025 Insight Molecular Diagnostics Inc. (IMDX) is expected to report for Q2 2025 Lightbridge Corporation (LTBR) is expected to report for Q2 2025 NewHold...

Spruce Biosciences Inc. (SPRB) is expected to report $-19.17 for Q2 2025

2025-07-24 16:15:20 ET More on Spruce Biosciences Spruce Biosciences gets conditional approval to resume trading on Nasdaq Capital Market Seeking Alpha’s Quant Rating on Spruce Biosciences Historical earnings data for Spruce Biosciences Financial infor...

Spruce’s Common Stock to Begin Trading on a Post-Split Adjusted Basis on August 5, 2025 Relisting on Nasdaq Capital Market Anticipated Following Compliance with Minimum Bid Price for 20 Consecutive Trading Days Spruce Biosciences, Inc. (OTCQB: SPRB), a late-stage biopha...